市场调查报告书
商品编码
1492632
霍乱疫苗市场:按类型、管理方法、最终用户、年龄组别划分 - 全球预测 2024-2030Cholera Vaccines Market by Type (Inactivated Vaccine, Live Attenuated Vaccine), Method of Administration (Injectable Vaccines, Oral Vaccines), End User, Age Group - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
霍乱疫苗市场规模预计2023年为2.8642亿美元,2024年达到3.0702亿美元,预计2030年将达到4.6983亿美元,复合年增长率为7.32%。
霍乱疫苗是生物製药,旨在保护个人免受霍乱的侵害,霍乱是一种由霍乱弧菌引起的严重腹泻疾病。这些疫苗会刺激人体的免疫反应,使其能够在接触霍乱弧菌后快速识别并抵抗霍乱弧菌。霍乱疫苗有两种:口服疫苗和注射疫苗,每种疫苗的效果和免疫持续时间不同。由于全球前往霍乱流行地区的旅行增加,霍乱疫苗的使用大幅增加,增加了旅客采取预防措施的需要。此外,人们对全球卫生工作的认识和国际支持的提高也增加了对脆弱地区疫苗接种计划的财政和后勤支援。然而,霍乱疫苗的推出面临一些挑战。在偏远和资源匮乏地区分发和管理疫苗的物流挑战阻碍了普及。此外,受年龄和是否存在预先存在的免疫力等因素影响,疫苗诱导的免疫力存在变异性,这使得不同人群中疫苗功效的测量变得复杂。儘管有这些挑战,疫苗技术的进步,例如单剂量疫苗和温度稳定製剂的开发,有可能显着提高疫苗宣传活动的实用性和有效性。此外,将霍乱疫苗接种计划与其他公共卫生工作相结合可以加强整体疾病控制并促进受影响地区更永续的健康改善。
主要市场统计 | |
---|---|
基准年[2023] | 2.8642亿美元 |
预计年份 [2024] | 30702万美元 |
预测年份 [2030] | 46983万美元 |
复合年增长率(%) | 7.32% |
区域洞察
霍乱疫苗市场由公共卫生需求和社会经济条件决定,并在世界不同地区表现出独特的特征。在美国,来自霍乱流行地区和某些移民社区的旅客对它有需求。此外,该地区强大的医疗保健和卫生系统也有利于霍乱疫苗接种计画。在欧洲,霍乱疫苗主要提供给前往流行地区的旅客和军事相关人员。中东和非洲的霍乱风险和发病率很高,主要是由于卫生条件不佳和清洁水供应不足,因此需要霍乱疫苗。在亚太地区,由于南亚和东南亚霍乱盛行率很高,因此对霍乱疫苗的需求很高。印度和孟加拉等国家深受霍乱影响,是该地区需求的主要驱动力。意识的提高和政府控制霍乱疫情的努力也支持了这些疫苗的稳定消费。
FPNV定位矩阵
FPNV 定位矩阵对于评估霍乱疫苗市场供应商的定位至关重要。此矩阵提供了对供应商的全面评估,并检查了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对霍乱疫苗市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对霍乱疫苗市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[199 Pages Report] The Cholera Vaccines Market size was estimated at USD 286.42 million in 2023 and expected to reach USD 307.02 million in 2024, at a CAGR 7.32% to reach USD 469.83 million by 2030.
Cholera vaccines are biological preparations designed to protect individuals from cholera, a severe diarrheal illness caused by the Vibrio cholerae bacteria. These vaccines stimulate the body's immune response, enabling it to quickly recognize and combat the cholera bacteria if exposed. There are several types of cholera vaccines available, including both oral and injectable forms, each with varying degrees of effectiveness and duration of immunity. The use of cholera vaccines has expanded considerably owing to the global increase in travel to areas where cholera is endemic, which has heightened the need for preventive measures among travelers. Further, growing awareness and international support for global health initiatives have increased funding and logistical support for vaccination programs in vulnerable regions. However, the deployment of cholera vaccines faces several challenges. Logistical difficulties in distributing and administering vaccines in remote or resource-limited areas hinder widespread coverage. Additionally, the variability in vaccine-induced immunity, which can be influenced by factors such as age and the presence of pre-existing immunity, complicates the measurement of vaccine effectiveness in different populations. Despite these challenges, advances in vaccine technology, such as the development of single-dose vaccines or temperature-stable formulations, could significantly improve the practicality and effectiveness of vaccination campaigns. Moreover, integrating cholera vaccination programs with other public health initiatives could enhance overall disease control and promote more sustainable health improvements in affected regions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 286.42 million |
Estimated Year [2024] | USD 307.02 million |
Forecast Year [2030] | USD 469.83 million |
CAGR (%) | 7.32% |
Regional Insights
The cholera vaccine market exhibits distinct characteristics across various global regions, shaped by public health needs and socio-economic conditions. In America, there is demand among travelers and certain immigrant communities from cholera-endemic regions. Further, robust healthcare and sanitation systems across the region facilitate cholera vaccination programs. Europe has a significant adoption of cholera vaccines, majorly among travelers and military personnel deployed to endemic regions. The Middle East and Africa face higher risks and incidences of cholera, primarily attributed to poor sanitation and inadequate access to clean water, generating a need for cholera vaccines. Asia-Pacific observes a significant need for the cholera vaccine owing to higher prevalence rates in South and Southeast Asia. Countries such as India and Bangladesh are heavily impacted by cholera, largely driving the need in the region. The increasing awareness and government initiatives to control cholera outbreaks also support the steady consumption of these vaccines.
Market Insights
The market dynamics represent an ever-changing landscape of the Cholera Vaccines Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cholera Vaccines Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cholera Vaccines Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Strategic Technology Transfer in Cholera Vaccination: A Partnership Between IVI and Biological E. Limited
South Korea's International Vaccine Institute (IVI) has initiated a technology transfer to Biological E. Limited (BE), an Indian vaccine and pharmaceutical company. This collaboration involves IVI providing BE with the necessary technical information, know-how, and materials to manufacture the simplified oral cholera vaccine (OCV-S) in India. This partnership intends to enhance the availability of affordable cholera vaccines for both the Indian market and globally. [Published On: 2024-03-21]
Strategic Collaboration for Cholera Vaccine Production between GC Biopharma and Eubiologics
GC Biopharma, a South Korean biopharmaceutical company, has entered into a memorandum of understanding with Eubiologics to collaboratively produce the oral cholera vaccine, Euvichol. Under this agreement, Eubiologics will manage the bulk manufacturing phase of the vaccine, while GC Biopharma will handle the packaging tasks, including the bottling of the vaccine into vials, ensuring a streamlined process for vaccine supply. [Published On: 2023-08-28]
TechInvention Introduces Innovative Cholera Vaccine Packaging in India with Eubiologics Partnership
Mumbai-based TechInvention Lifecare, in collaboration with South Korea's Eubiologics Co., has introduced Euvichol-Plus, an oral cholera vaccine encased in a low-density polyethylene (LDPE) unidose pack. This innovative packaging solution addresses several issues associated with traditional glass vials, including risks of breakage and challenges in storage, transportation, handling, and disposal. [Published On: 2023-05-12]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cholera Vaccines Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cholera Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Beijing Minhai Biological Technology Co., Ltd., Bharat Biotech Ltd., Bio-Manguinhos, Biological E Ltd, BioVac by Ceva Sante Animale, Emergent BioSolutions Inc., GlaxoSmithKline plc, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Merck & Co. Inc, Panacea Biotec Ltd, Sanofi S.A., SK Inc., Techinvention Lifecare Pvt. Ltd., and Valneva SE.
Market Segmentation & Coverage